{"doi":"10.17615/43bn-jd52","title":"Psychometric validation of the BDI-II among HIV-positive CHARTER study participants.","abstract":"Rates of depression are high among individuals living with HIV. Accurate assessment of depressive symptoms among this population is important for ensuring proper diagnosis and treatment. The Beck Depression Inventory-II (BDI-II) is a widely used measure for assessing depression, however its psychometric properties have not yet been investigated for use with HIV-positive populations in the U.S. The current study was the first to assess the psychometric properties of the BDI-II among a large cohort of HIV-positive participants sampled at multiple sites across the U.S. as part of the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) study. The BDI-II test scores showed good internal consistency (α = 0.93) and adequate test-retest reliability (ICC = 0.83) over a 6-month period. Using a ‘gold standard’ of major depressive disorder determined by the Composite International Diagnostic Interview (CIDI), sensitivity and specificity were maximized at a total cut-off score of 17 and a Receiver Operating Characteristic (ROC) analysis confirmed that the BDI-II is an adequate diagnostic measure for the sample (AUC = 0.83). The sensitivity and specificity of each score are provided graphically. Confirmatory factor analyses confirmed the best fit for a 3-factor model over 1-factor and 2-factor models and models with a higher-order factor included. The results suggest that the BDI-II is an adequate measure for assessing depressive symptoms among U.S. HIV-positive patients. Cut-off scores should be adjusted to enhance sensitivity or specificity as needed and the measure can be differentiated into cognitive, affective, and somatic depressive symptoms.","journal":"UNC Libraries","year":2020,"id":143047,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9425,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":312161,"name":"Robert K. Heaton","orcid":"0000-0002-6664-8016","position":1,"is_corresponding":false},{"id":610103,"name":"Amy J. Starosta","orcid":"0000-0002-6449-4842","position":2,"is_corresponding":false},{"id":492753,"name":"Andréa L. Hobkirk","orcid":"0000-0002-3020-3963","position":3,"is_corresponding":false},{"id":378403,"name":"Christina M. Marra","orcid":"0000-0001-9313-2800","position":4,"is_corresponding":false},{"id":512394,"name":"Mitch Earleywine","orcid":"0000-0002-6870-0623","position":5,"is_corresponding":false},{"id":610102,"name":"Joseph A. De Leo","orcid":"0000-0002-1793-119X","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-18T23:17:34.768426Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}